Download PDF

1. Company Snapshot

1.a. Company Description

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally.It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services.


In addition, it markets and sells veterinary drugs manufactured by other international companies.The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets.Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics.


Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Show Full description

1.b. Last Insights on ORNAV

Orion Oyj's recent performance was driven by record financial results, including all-time high net sales and operating profit. The company's robust Q4 performance was fueled by significant revenue growth, strategic milestones, and a positive outlook for 2026. Nubeqa's milestone payment of €180 million and progress in oncology-focused R&D also contributed to the performance. Additionally, the company's proposal to pay a €1.80 per share dividend in 2026 and a new long-term incentive program tied to financial, pipeline, and ESG targets align management rewards with shareholder interests.

1.c. Company Highlights

2. Orion's Strong FY2025 Results Driven by Nubeqa Milestone and Organic Growth

Orion's financial performance in FY2025 was robust, with net sales reaching EUR 2.6 billion, representing a 22.5% growth including a EUR 180 million milestone from Bayer related to Nubeqa. The operating profit margin expanded to 33.4% from 27% in the previous year, driven by a 59% growth in operating profit to EUR 1.03 billion. Earnings per share (EPS) came in at EUR 1.85, slightly below estimates of EUR 1.98. The company's base business grew by 21%, with all divisions contributing to the growth. As Liisa Hurme, CEO, noted, "Our business divisions had a strong quarter, with all divisions performing extremely well."

Publication Date: Feb -14

📋 Highlights
  • Q4 Sales Growth:: 18.5% base business growth (60% including EUR 180M Nubeqa milestone) and 59% operating profit growth (47% margin).
  • Full-Year Net Sales:: EUR 2.6B (21% base growth, 22.5% including milestone) and EUR 1.03B operating profit (59% base growth, 52% including milestone).
  • Divisional Growth:: Innovative Medicines up 38% (driven by milestone), Branded Products +10%, Animal Health +10%, and Generics/Consumer Health +5.7%.
  • 2026 Guidance:: Net sales EUR 1.9B–2.1B and operating profit EUR 550M–750M, with R&D expenses expected to rise due to pipeline advancements.
  • Dividend Proposal:: EUR 1.80/share to be paid in two installments, reflecting confidence in sustained profitability.

Segmental Performance

The Innovative Medicines division saw a 38% growth, primarily due to the Nubeqa milestone. The Branded Products division grew by 10%, driven by the budesonide-formoterol combination product and Stalevo. The Generics and Consumer Health division recorded a 5.7% growth, driven by launches in current territories and patent expiries. The Animal Health division grew by 10%, driven by a broad geographic presence and portfolio.

Guidance and Outlook

Orion's guidance for FY2026 indicates net sales between EUR 1.9 billion and EUR 2.1 billion, with an operating profit range of EUR 550 million to EUR 750 million. Analysts estimate revenue growth at 11.2% for next year. The company's R&D expenses are expected to increase as it advances its clinical pipeline, including the initiation of combination studies for ODM-212 and the entry of a biologic product into the clinical stage.

Valuation

With a P/E Ratio of 30.48 and an EV/EBITDA of 22.71, Orion's valuation suggests that the market has priced in significant growth expectations. The Dividend Yield stands at 2.42%, with a proposed dividend of EUR 1.80 per share for FY2025. The ROE of 31.24% and ROIC of 22.82% indicate strong profitability. The Net Debt / EBITDA ratio of 0.21 suggests a healthy balance sheet.

Key Drivers

Nubeqa's growth, driven by early-stage indications, is expected to continue, with royalties from Bayer contributing to Orion's revenue. The company's R&D pipeline advancements and sales and marketing expenses will be key drivers of future performance. The external sales of Fermion and the impact of FX will also influence the company's financials.

3. NewsRoom

Card image cap

Orion Group Financial Statement documents 2025 and Remuneration Report published

Feb -27

Source:

Card image cap

Orion Oyj Record 2025 Results Put Board Changes And Valuation In Focus

Feb -15

Source:

Card image cap

Does Orion Oyj (HLSE:ORNBV) Dividend Hike Clarify Its Oncology-Pivot Capital Allocation Strategy?

Feb -14

Source:

Card image cap

Orion Oyj (ORINY) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Developments

Feb -12

Source:

Card image cap

The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons

Feb -12

Source:

Card image cap

Notice to the Annual General Meeting of Orion Corporation

Feb -12

Source:

Card image cap

Orion Group Financial Statement Release January–December 2025

Feb -12

Source:

Card image cap

Assessing Orion Oyj (HLSE:ORNBV) Valuation After A Strong 1 Year Shareholder Return

Feb -06

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.51%)

6. Segments

Generics and Consumer Health

Expected Growth: 8.5%

Orion Oyj's Generics and Consumer Health segment growth of 8.5% is driven by increasing demand for affordable medicines, strategic product launches, and expansion into emerging markets. Additionally, the company's focus on R&D and partnerships has enabled it to capitalize on opportunities in the growing self-care market, further boosting segment growth.

Branded Products

Expected Growth: 8.0%

Orion Oyj's branded products growth is driven by increasing demand for specialty pharmaceuticals, particularly in the oncology and respiratory therapy segments. Strong product pipeline, strategic partnerships, and expansion into emerging markets also contribute to the 8.0% growth. Additionally, investments in digitalization and operational efficiency enable the company to maintain a competitive edge.

Innovative Medicines

Expected Growth: 9.5%

Orion Oyj's Innovative Medicines segment growth is driven by strong demand for its Easyhaler product portfolio, particularly in Europe and Japan. The company's strategic investments in R&D, successful product launches, and expanding presence in emerging markets also contribute to its 9.5% growth. Additionally, Orion's focus on specialty care and rare diseases, as well as its partnerships and collaborations, further support its growth momentum.

Animal Health

Expected Growth: 7.5%

Orion Oyj's Animal Health segment growth of 7.5% is driven by increasing pet ownership, rising demand for veterinary care, and growing awareness of animal health. Additionally, the company's strong product portfolio, including veterinary pharmaceuticals and diagnostics, contributes to its growth. Expanding distribution channels and strategic partnerships also support the segment's growth.

Fermion

Expected Growth: 8.8%

Fermion from Orion Oyj's 8.8% growth is driven by increasing demand for pharmaceuticals, strategic partnerships, and expansion into emerging markets. Additionally, investments in R&D, process optimization, and cost savings initiatives contribute to the company's growth momentum.

Translation Differences and Other Operations

Expected Growth: 6.0%

Orion Oyj's 6.0% growth in Translation Differences and Other Operations is driven by favorable currency fluctuations, strategic acquisitions, and improved operational efficiency. Additionally, the company's diversified product portfolio and expansion into emerging markets have contributed to the growth. Furthermore, effective cost management and investments in digital transformation have also supported the segment's growth.

7. Detailed Products

Orion Pharma

Develops and manufactures pharmaceuticals, including prescription and self-care products

Orion Diagnostica

Develops and manufactures diagnostic tests and instruments for healthcare professionals

Orion Animal Health

Develops and manufactures veterinary pharmaceuticals and feed additives for animal health

Contract Manufacturing

Provides contract manufacturing services for pharmaceutical and biotechnology companies

Active Pharmaceutical Ingredients (APIs)

Develops and manufactures active pharmaceutical ingredients for pharmaceutical companies

8. Orion Oyj's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Orion Oyj is medium, as there are some alternatives available in the market, but they are not very attractive to customers.

Bargaining Power Of Customers

The bargaining power of customers for Orion Oyj is low, as customers have limited options and the company has a strong brand presence.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Orion Oyj is medium, as the company relies on a few key suppliers, but has some flexibility in its supply chain.

Threat Of New Entrants

The threat of new entrants for Orion Oyj is high, as the industry has low barriers to entry and new companies can easily enter the market.

Intensity Of Rivalry

The intensity of rivalry for Orion Oyj is high, as the company operates in a highly competitive industry with many established players.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 18.35%
Debt Cost 3.95%
Equity Weight 81.65%
Equity Cost 5.64%
WACC 5.33%
Leverage 22.47%

11. Quality Control: Orion Oyj passed 7 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Sanofi

A-Score: 5.9/10

Value: 6.2

Growth: 4.0

Quality: 8.0

Yield: 7.5

Momentum: 2.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Orion

A-Score: 5.9/10

Value: 1.1

Growth: 5.3

Quality: 8.1

Yield: 6.2

Momentum: 9.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Recordati

A-Score: 5.8/10

Value: 2.7

Growth: 6.2

Quality: 8.5

Yield: 5.0

Momentum: 4.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Qiagen

A-Score: 5.0/10

Value: 2.7

Growth: 4.6

Quality: 7.0

Yield: 4.4

Momentum: 2.5

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Virbac

A-Score: 4.9/10

Value: 3.3

Growth: 6.3

Quality: 6.5

Yield: 0.6

Momentum: 6.0

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
Rovi

A-Score: 4.8/10

Value: 1.8

Growth: 7.7

Quality: 8.1

Yield: 2.5

Momentum: 3.0

Volatility: 6.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

67.3$

Current Price

67.3$

Potential

-0.00%

Expected Cash-Flows